All News

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.

Fezolinetant (Veozah) was linked to objective and patient-reported sleep gains in OPTION-VMS, with no new safety signals observed.

HPV vaccination before pregnancy was linked to lower odds of preterm birth in a Swedish study of 624,713 births.

The prospective SOARA study will measure how often a 98%-specific ovarian cancer screening blood test leads to invasive procedures.

A new 3-part Lancet series reframes pregnancy as a cardiovascular risk window.

Wen Shen, MD, explains how clinicians can counter menopause misinformation from social media and steer patients toward evidence-based resources.

Wen Shen, MD, outlines when to treat perimenopausal symptoms and which history-taking red flags should prompt earlier bone and cardiovascular screening or referral.

Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.

Jean Cunningham, PharmD, BCPS, explains how ob-gyns can link anxiety, sleep disruption, and cognitive changes to perimenopause—and catch it earlier.

The well-woman visit drives preventive care, but its structure leaves little room for the complexity of women's lives, according to Barbara Levy, MD.

A review finds post-miscarriage ultrasound heterogeneity is common and that symptoms, not endometrial thickness, should guide management after EPL.

Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.

Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.

Wen Shen, MD, describes perimenopause as an opportunity for clinicians to revisit pregnancy-related risk factors and address cardiovascular health proactively.

A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.

A new study finds that low birth volume and unprofitability were strongly associated with both obstetric unit and full hospital closures between 2010 and 2023.

A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.

A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.

Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.

Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.

A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.

The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.

AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.

CDC data show gestational hypertension rose 73% from 2016 to 2024, affecting 1 in 10 US mothers giving birth.

Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.

The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.

Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.